Phase 3 N=292 Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
Chronic Schizophrenia
Primary: Relapse of Psychotic Symptoms — 29; 21 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=75 Efficacy of Lansoprazole in Chronic Post Nasal Drip
Larynx Disease
Primary: Post Nasal Drainage Symptom Response — 55; 3.5; 50; 5 Scores on a Scale — p=.01
Phase 3 N=315 Effect of pH and Fluoride Concentration of Dentifrices on Caries Control
Dental Fluorosis · Dental Caries
Primary: Evaluation of the Concentration of Fluoride Incorporated Into the Biofilm Done 6 Months After Initiation of Dentifrices Use. — 0.80; 1.32; 1.74 mmol/kg — p=<0.05
Phase 3 N=161 Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
Cystic Fibrosis
Primary: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 — -0.2; 10.4 percent of predicted volume (L)…
Phase 3 N=52 Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
Cystic Fibrosis
Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 — 0.1; 12.6 percent of predicted volume (L) — p=<0.0001
Phase 3 N=189 Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
Hepatitis C
Primary: The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained…
Phase 3 N=32 Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
Hepatitis C
Primary: The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained…
Phase 3 N=109 Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
Chronic Hepatitis C
Primary: The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained…
Phase 3 N=218 Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain
Pain
Primary: Time-weighted Sum of Pain Relief Rating With Pain Intensity Difference From 0 to 6 Hours (SPRID 0-6) — 2.8; 20.0; 17.1 units on a scale — p=<0.001
Phase 3 N=16 The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression
Psychotic Depression
Primary: Depression and Psychosis Response Rate — 62.5 percent of participants
Phase 3 N=200 Study Evaluating A Novel Ibuprofen Formulation In Episodic Tension-Type Headache
Pain
Primary: Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet — 11.2; 10.8 Units on a scale…
Phase 3 N=303 Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 30 — -1.87; -1.54 percentage of total hemoglobin — p=0.0023
Phase 3 N=137 A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
Multiple Sclerosis · Spasticity
Primary: Incidence of Adverse Events as a Measure of Patient Safety — 126 participants
Phase 3 N=316 Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain
Pain
Primary: Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-8 Hours (SPRID 0-8) — 5.4; 29.8 Units on a scale — p=<0.001
Phase 3 N=25 Cerebral Oximetry and Neurological Outcomes in Aortic Arch Surgery Patients
Postoperative Cognitive Dysfunction
Primary: Mini Mental State Examination (MMSE) — 27; 26.769 scores on a scale — p=0.678